GeoVax Labs (GOVX) Projected to Post Quarterly Earnings on Monday

GeoVax Labs (NASDAQ:GOVX) is expected to be announcing its Q2 2026 results after the market closes on Monday, July 27th. Analysts expect GeoVax Labs to post earnings of ($2.16) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Thursday, May 14th. The company reported ($2.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.84) by $1.22. On average, analysts expect GeoVax Labs to post $-9 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GeoVax Labs Price Performance

GeoVax Labs stock opened at $0.97 on Monday. The firm’s fifty day moving average is $1.59 and its 200 day moving average is $1.96. The company has a market cap of $3.38 million, a price-to-earnings ratio of -0.05 and a beta of 3.68. GeoVax Labs has a 52-week low of $0.82 and a 52-week high of $23.10.

Analyst Upgrades and Downgrades

Several equities analysts have commented on GOVX shares. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. Finally, D. Boral Capital reissued a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $150.00.

Institutional Trading of GeoVax Labs

Several institutional investors and hedge funds have recently bought and sold shares of GOVX. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs in the first quarter valued at about $27,000. HRT Financial LP purchased a new position in shares of GeoVax Labs in the fourth quarter valued at $31,000. Renaissance Technologies LLC acquired a new position in shares of GeoVax Labs during the 4th quarter worth $104,000. Finally, Armistice Capital LLC acquired a new stake in shares of GeoVax Labs in the third quarter valued at approximately $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.